Skip to main content
SpringerLink
Log in

Emtricitabine/tenofovir disoproxil fumarate in HIV-1 pre-exposure prophylaxis: a guide to its once-daily use in the EU

  • Adis Drug Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

The fixed-dose combination of emtricitabine/tenofovir disoproxil fumarate (tenofovir DF) [Truvada®] is approved in the EU for pre-exposure prophylaxis, in conjunction with safer sex practices, to reduce the risk of sexually-acquired HIV-1 infection in adults at high risk. Once-daily administration of emtricitabine/tenofovir DF was effective in preventing HIV-1 infection in clinical trials in high-risk populations, including men who have sex with men, heterosexual HIV-1-serodiscordant couples, and heterosexual men and women. As adherence to the regimen correlates with the risk of HIV-1 infection, it is important that patient adhere to pre-exposure prophylaxis. Pre-exposure prophylaxis with the combination was generally well tolerated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Krakower D, Mayer KH. What primary care providers need to know about preexposure prophylaxis for HIV prevention: a narrative review. Ann Intern Med. 2012;157(7):490–7.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Padian NS, McCoy SI, Karim SS, et al. HIV prevention transformed: the new prevention research agenda. Lancet. 2011;378(9787):269–78.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Marrazzo JM, Cates W. Interventions to prevent sexually transmitted infections, including HIV infection. Clin Infect Dis. 2011;53(Suppl 3):S64–78.

    Article  PubMed  PubMed Central  Google Scholar 

  4. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 (2016 interim update). London: British HIV Association: 2016.

  5. European AIDS Clinical Society Guidelines: version 8.1 October 2016. Brussels: European AIDS Clinical Society; 2016.

  6. Truvada 200 mg/245 mg film-coated tablets: summary of product characteristics. London: European Medicines Agency; 2016.

  7. Perry CM. Emtricitabine/tenofovir disoproxil fumarate: in combination with a protease inhibitor in HIV-1 infection. Drugs. 2009;69(7):843–57.

    Article  CAS  PubMed  Google Scholar 

  8. Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet. 2004;43(9):595–612.

    Article  CAS  PubMed  Google Scholar 

  9. Ruone S, Paxton L, McLaurin T, et al. HIV-1 evolution in breakthrough infections in a human trial of oral pre- exposure prophylaxis with emtricitabine and tenofovir disoproxil fumarate. J Acquir Immune Defic Syndr. 2015;72(2):129–32.

    Article  Google Scholar 

  10. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509–18.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Lehman DA, Baeten JM, McCoy CO, et al. Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single-or dual-agent preexposure prophylaxis. J Infect Dis. 2015;211(8):1211–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Liegler T, Abdel-Mohsen M, Bentley LG, et al. HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial. J Infect Dis. 2014;210(8):1217–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Parikh UM, Mellors JW. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis? Curr Opin HIV AIDS. 2016;11(1):49–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34.

    Article  CAS  PubMed  Google Scholar 

  17. Weis JF, Baeten JM, McCoy CO, et al. Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessation. AIDS. 2016;30(1):31–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10013):53–60.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Baeten JM, Donnell D, Mugo NR, et al. Single-agent tenofovir versus combination emtricitabine/tenofovir for pre-exposure prophylaxis against HIV-1 acquisition: a randomised trial. Lancet Infect Dis. 2014;14(11):1055–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Murnane PM, Celum C, Mugo N, et al. Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial. AIDS. 2013;27(13):2155–60.

    Article  CAS  PubMed  Google Scholar 

  21. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–22.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Corneli AL, Deese J, Wang M, et al. FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis. J Acquir Immune Defic Syndr. 2014;66(3):324–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Donnell D, Baeten JM, Bumpus NN, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014;66(3):340–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Blumenthal J, Haubrich RH. Will risk compensation accompany pre-exposure prophylaxis for HIV? Virtual Mentor. 2014;16(11):909–15.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Marcus JL, Glidden DV, Mayer KH, et al. No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis. PLoS One. 2013;8(12):e81997.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Mugwanya KK, Donnell D, Celum C, et al. Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: a longitudinal analysis. Lancet Infect Dis. 2013;13(12):1021–8.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Koester K, Amico R, Liu A, et al. Sex on PrEP: qualitative findings from the iPrEx open label extension (OLE) in the US [abstract no. TUAC0102]. In: 20th International AIDS Conference; 2014.

  28. Mandala J, Nanda K, Wang M, et al. Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial. BMC Pharmacol Toxicol. 2014;15:77.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Solomon MM, Lama JR, Glidden DV, et al. Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. AIDS. 2014;28(6):851–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Mugwanya KK, Wyatt C, Celum C, et al. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial. JAMA Intern Med. 2015;175(2):246–54.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Mugwanya KK, Wyatt C, Celum C, et al. Reversibility of glomerular renal function decline in HIV-uninfected men and women discontinuing emtricitabine-tenofovir disoproxil fumarate pre-exposure prophylaxis. J Acquir Immune Defic Syndr. 2016;71(4):374–80.

    Article  CAS  PubMed  Google Scholar 

  32. Were EO, Heffron R, Mugo NR, et al. Pre-exposure prophylaxis does not affect the fertility of HIV-1-uninfected men. AIDS. 2014;28(13):1977–82.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Mugo NR, Hong T, Celum C, et al. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial. JAMA. 2014;312(4):362–71.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Kasonde M, Niska RW, Rose C, et al. Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana. PLoS ONE. 2014;9(3):e90111.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Mulligan K, Glidden DV, Anderson PL, et al. Effects of emtricitabine/tenofovir on bone mineral density in HIV-negative persons in a randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2015;61(4):572–80.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Solomon MM, Schechter M, Liu AY, et al. The safety of tenofovir-emtricitabine for HIV pre-exposure prophylaxis (PrEP) in individuals with active hepatitis B. J Acquir Immune Defic Syndr. 2016;71(3):281–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Kibengo FM, Ruzagira E, Katende D, et al. Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial. PLoS One. 2013;8(9):e74314.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Molina J-M, Capitant C, Spire B, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373(23):2237–46.

    Article  CAS  PubMed  Google Scholar 

  39. Molina J-M. French PrEP RTU protocol: summary patient report Sep 23rd 2016 [slide presentation]. Foster City: Gilead Sciences; 2016 (data on file).

  40. Baeten JM, Heffron R, Kidoguchi L, et al. Integrated delivery of antiretroviral treatment and pre-exposure prophylaxis to HIV-1-serodiscordant couples: a prospective implementation study in Kenya and Uganda. PLoS Med. 2016;13(8):e1002099.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Hurt CB, Eron JJ Jr, Cohen MS. Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? Clin Infect Dis. 2011;53(12):1265–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Greig SL, Deeks ED. Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide: a review in HIV-1 infection. Drugs. 2016;76(9):957–68.

    Article  CAS  PubMed  Google Scholar 

  43. Descovy 200 mg/10 mg film-coated tablets: summary of product characteristics. London: European Medicines Agency; 2016.

  44. Gilead Sciences. Safety and efficacy of emtricitabine and tenofovir alafenamide (F/TAF) fixed-dose combination once daily for pre-exposure prophylaxis in men and transgender women who have sex with men and are at risk of HIV-1 infection [ClinicalTrials.gov identifier NCT02842086]. US National Institutes of Heath. Clinical Trials.gov https://clinicaltrials.gov/ct2/show/NCT02842086. Accessed 4 Nov 2016.

  45. Plosker GL. Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis. Drugs. 2013;73(3):279–91.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The manuscript was updated from Drugs 2013;73(3):279–91 [45], and was reviewed by: T. Farazmandfer, Medical Cellular and Molecular Research Center, Golestan University of Medical Sciences, Gorgan, Iran; S. McCormack, Medical Research Council, Clinical Trials Unit at University College London, London, UK; L. Van Damme, Global Health Program—HIV, Bill & Melinda Gates Foundation, Seattle (WA), USA. During the peer review process, the manufacturer of Truvada® was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand

    Emma D. Deeks, Katherine Lyseng-Williamson & Greg L. Plosker

Authors
  1. Emma D. Deeks
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katherine Lyseng-Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Greg L. Plosker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine Lyseng-Williamson.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

E. Deeks, K.A. Lyseng-Williamson and G.L. Plosker are salaried employees of Adis/Springer, are responsible for the article content and declare no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Deeks, E.D., Lyseng-Williamson, K. & Plosker, G.L. Emtricitabine/tenofovir disoproxil fumarate in HIV-1 pre-exposure prophylaxis: a guide to its once-daily use in the EU. Drugs Ther Perspect 33, 8–15 (2017). https://doi.org/10.1007/s40267-016-0363-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-016-0363-9

Keywords

Search

Navigation